Premier Path Wealth Partners
VRTX icon

Premier Path Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Premier Path Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$915K Hold
1,751
– – 0.11% 181
2026
Q2 		$870K Sell
1,751
-119
-6% -$52.7K 0.1% 185
2026
Q1 		$835K Buy
1,870
+62
+3% +$28.9K 0.11% 181
2025
Q4 		$820K Buy
1,808
+118
+7% +$50.9K 0.11% 185
2025
Q3 		$662K Sell
1,690
-145
-8% -$60.6K 0.09% 225
2025
Q2 		$817K Buy
1,835
+45
+3% +$20.7K 0.11% 190
2025
Q1 		$868K Buy
1,790
+104
+6% +$48.5K 0.14% 178
2024
Q4 		$679K Buy
1,686
+80
+5% +$37.1K 0.1% 193
2024
Q3 		$747K Buy
1,606
+28
+2% +$13.4K 0.12% 180
2024
Q2 		$740K Buy
1,578
+174
+12% +$75.5K 0.13% 173
2024
Q1 		$587K Buy
1,404
+18
+1% +$7.61K 0.11% 185
2023
Q4 		$564K Buy
+1,386
New +$512K 0.12% 175

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Premier Path Wealth Partners's VRTX Position: Q3 2026 in Review

Premier Path Wealth Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 1,751 shares worth $915K. The position accounts for 0.11% of the portfolio, ranked #181.

Premier Path Wealth Partners first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. 408 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Premier Path Wealth Partners held 1,751 shares of Vertex Pharmaceuticals worth $915K as of Q3 2026.
  • Premier Path Wealth Partners left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up 0.11% of Premier Path Wealth Partners's portfolio in Q3 2026, its #181 holding.
  • Premier Path Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • 408 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Premier Path Wealth Partners's 13F filing for Q3 2026, filed 16 Oct 2026.